IMCS designs, manufactures, and distributes next-generation recombinant proteins and chromatography consumables to toxicology laboratories, academic research facilities, US government agencies, and life science companies worldwide. IMCS has two product lines: IMCSzyme® and IMCStips®. The industry-disrupting IMCSzyme is a genetically modified enzyme for drug screening and analysis of urine and other biological samples. IMCStips utilize patented dispersive solid-phase extraction (dSPE) technology to purify proteins, antibodies, and enzymes, as part of drug discovery from validation to development, screening, and manufacturing. Recently, IMCS was awarded NIH funds to manufacture various glycosyltransferases to leverage the company’s advanced manufacturing and research capabilities to expand the synthesis of glycosphingolipids and sialoglycans. IMCS glyco-enzymes will deliver critically needed biological reagents to drive scientific discovery for neurodegenerative disease research.